Deanne Miller - Immutep Insider

PRRUF -- USA Stock  

USD 0.015  0.005  25.00%

General Counsel, Company Secretary

Ms. Deanne Miller, LLB, serves as Chief Operating Officer, General Counsel, Company Secretary of Prima BioMed Ltd. Ms Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.
Age: 38  Executive Since 2016      
61 2 8315 7003  http://www.primabiomed.com.au
Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Management Efficiency

The company has return on total asset (ROA) of (17.71) % which means that it has lost $17.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (32.99) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.77 M in total debt with debt to equity ratio (D/E) of 22.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Immutep Limited has Current Ratio of 7.97 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep is traded on OTC Market in USA.Immutep Limited (PRRUF) is traded on OTC Market in USA. It is located in 95 Pitt Street and employs 31 people.

Immutep Limited Leadership Team

Pete Meyers, Director, MBA
Russell Howard, Director, Ph.D
Larisa Chisholm, Executive
Tom Bloomfield, Executive
YueLing Wong, Chairman
Frederic Triebel, Executive
Deanne Miller, Executive
Sharron Gargosky, Executive, Ph.D
Grant Chamberlain, Director
Lucy Turnbull, Chairman
Marc Voigt, CEO
Matthew Gregorowski, Executive

Stock Performance Indicators

Current Sentiment - PRRUF

Immutep Limited Investor Sentiment
Macroaxis portfolio users are evenly split in their perspective on investing in Immutep Limited. What is your judgment towards investing in Immutep Limited? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
few days ago
Traded for 10.44
FBU   
Purchased over 300 shares of
few days ago
Traded for 6.24
JBH   
Purchased over 70 shares of
few days ago
Traded for 23.42
GNC   
Purchased over 200 shares of
few days ago
Traded for 8.1
SBM   
Purchased over 400 shares of
few days ago
Traded for 4.74
Additionally take a look at Your Equity Center. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.